They have gotten involved in lightening the regulatory burden for certain drugs that are orphaned or for rare diseases, which is essentially a subsidy.

Also, the number of drug company booths at a recent infectious disease conference I went to suggests this whole "No interest in drugs that cure in three weeks" thing is...well...not actually true. These are incredibly common infections, there's plenty of market for them. Hell, the compound was initially discovered by Bayer.